Search alternatives:
significant mean » significant main (Expand Search), significant green (Expand Search), significant gap (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
significant mean » significant main (Expand Search), significant green (Expand Search), significant gap (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
-
141
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
142
-
143
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
144
-
145
-
146
-
147
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
148
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
149
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
150
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
151
-
152
-
153
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
154
-
155
-
156
-
157
-
158
-
159
B2 decreases glycolytic intermediates in cells.
Published 2025“…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …”
-
160